NL-OMON38428尚未招募不适用
Vascular Response to Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in patients with Diabetes Mellitus - BVS-DM First
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Patient is at least 18 years of age.
- •2. Patient is know with diabetes mellitus
- •3. Patient presenting with NSTEMI, stable or unstable angina , or silent ischemia caused by a de novo stenotic lesion in a native previous untreated coronary artery
- •4. Dmax (proximal and distal mean lumen diameter) within the upper limit of 3.8 mm and the lower limit of 2.0 mm by online QCA (at the moment only for the 2.5 mm and 3.5 mm devices)
- •5. The patient understands and accepts the meaning and the aims of the study
- •6. The patient is willing to comply with specified follow-up evaluation and can be contacted by telephone (Signed Informed Consent)
排除标准
- •1. Previous CABG
- •2. Cardiogenic shock
- •3. STEMI patients requiring immediate stent implantation
- •4. Bifurcation lesion requiring kissing balloon postdilatation
- •5. Allergies or contraindications to antiplatelet medication or contrast material
- •6. Female patient with child bearing potential not taking adequate contraceptives or currently breasfeeding
- •7. Expected survival of < 1 year
研究者
相似试验
已完成
不适用
ong-Term Vascular Response to Everolimus-Eluting Stent: Five-year Follow-up Optical Coherence Tomography StudyCoronary artery diseaseJPRN-UMIN000018860Department of Cardiology, Kokura Memorial Hospital40
终止
不适用
Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total OcclusionCoronary Artery DiseaseNCT02739685University of Luebeck17
进行中（未招募）
1 期
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
终止
不适用
EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes MellitusDiabetes MellitusCoronary Artery DiseaseNCT02632292University of Luebeck33
招募中
Unknown
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20